Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rönnstrand L[au]:

Search results

Items: 1 to 50 of 150

1.

Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.

Li T, Deng Y, Shi Y, Tian R, Chen Y, Zou L, Kazi JU, Rönnstrand L, Feng B, Chan SO, Chan WY, Sun J, Zhao H.

Oncogene. 2018 Jul 16. doi: 10.1038/s41388-018-0397-7. [Epub ahead of print]

PMID:
30013190
2.

XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation.

Sun J, Thingholm T, Højrup P, Rönnstrand L.

Oncogenesis. 2018 Jun 18;7(6):48. doi: 10.1038/s41389-018-0057-3.

3.

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.

Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishan R, Garcia-Ruiz C, Nance S, Gupta P, Zhang J, Rönnstrand L, Hultquist A, Downing JR, Lindkvist-Petersson K, Paulsson K, Järås M, Gruber TA, Ma J, Hagström-Andersson AK.

Nat Commun. 2018 May 2;9(1):1770. doi: 10.1038/s41467-018-04180-1.

4.

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.

Rupar K, Moharram SA, Kazi JU, Rönnstrand L.

Sci Rep. 2018 Apr 23;8(1):6405. doi: 10.1038/s41598-018-24743-y.

5.

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.

Marhäll A, Heidel F, Fischer T, Rönnstrand L.

Ann Hematol. 2018 May;97(5):773-780. doi: 10.1007/s00277-018-3245-5. Epub 2018 Jan 25.

6.

The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation.

Marhäll A, Kazi JU, Rönnstrand L.

Sci Rep. 2017 Oct 23;7(1):13734. doi: 10.1038/s41598-017-14033-4.

7.

KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma.

Phung B, Kazi JU, Lundby A, Bergsteinsdottir K, Sun J, Goding CR, Jönsson G, Olsen JV, Steingrímsson E, Rönnstrand L.

Mol Cancer Res. 2017 Sep;15(9):1265-1274. doi: 10.1158/1541-7786.MCR-17-0149. Epub 2017 Jun 5.

8.

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.

Kazi JU, Chougule RA, Li T, Su X, Moharram SA, Rupar K, Marhäll A, Gazi M, Sun J, Zhao H, Rönnstrand L.

Cell Mol Life Sci. 2017 Jul;74(14):2679-2688. doi: 10.1007/s00018-017-2494-0. Epub 2017 Mar 7.

9.

ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.

Kazi JU, Rupar K, Marhäll A, Moharram SA, Khanum F, Shah K, Gazi M, Nagaraj SR, Sun J, Chougule RA, Rönnstrand L.

Oncotarget. 2017 Feb 14;8(7):12194-12202. doi: 10.18632/oncotarget.14577.

10.

Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.

Moharram SA, Chougule RA, Su X, Li T, Sun J, Zhao H, Rönnstrand L, Kazi JU.

Oncotarget. 2016 Sep 6;7(36):57770-57782. doi: 10.18632/oncotarget.10760.

11.

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.

Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21.

12.

Expression of GADS enhances FLT3-induced mitogenic signaling.

Chougule RA, Cordero E, Moharram SA, Pietras K, Rönnstrand L, Kazi JU.

Oncotarget. 2016 Mar 22;7(12):14112-24. doi: 10.18632/oncotarget.7415.

13.

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.

14.

FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.

Chougule RA, Kazi JU, Rönnstrand L.

Oncotarget. 2016 Mar 1;7(9):9964-74. doi: 10.18632/oncotarget.7128.

15.

The role of HOXB2 and HOXB3 in acute myeloid leukemia.

Lindblad O, Chougule RA, Moharram SA, Kabir NN, Sun J, Kazi JU, Rönnstrand L.

Biochem Biophys Res Commun. 2015 Nov 27;467(4):742-7. doi: 10.1016/j.bbrc.2015.10.071. Epub 2015 Oct 22.

PMID:
26482852
16.

Brain-Expressed X-linked (BEX) proteins in human cancers.

Kazi JU, Kabir NN, Rönnstrand L.

Biochim Biophys Acta. 2015 Dec;1856(2):226-33. doi: 10.1016/j.bbcan.2015.09.001. Epub 2015 Sep 25. Review.

PMID:
26408910
17.

The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness.

Zhang J, Vakhrusheva O, Bandi SR, Demirel Ö, Kazi JU, Fernandes RG, Jakobi K, Eichler A, Rönnstrand L, Rieger MA, Carpino N, Serve H, Brandts CH.

Stem Cell Reports. 2015 Oct 13;5(4):633-46. doi: 10.1016/j.stemcr.2015.08.006. Epub 2015 Sep 10.

18.

BEX1 acts as a tumor suppressor in acute myeloid leukemia.

Lindblad O, Li T, Su X, Sun J, Kabir NN, Levander F, Zhao H, Lu G, Rönnstrand L, Kazi JU.

Oncotarget. 2015 Aug 28;6(25):21395-405.

19.

PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.

Lindblad O, Kazi JU, Rönnstrand L, Sun J.

Cell Mol Life Sci. 2015 Nov;72(22):4399-407. doi: 10.1007/s00018-015-1944-9. Epub 2015 Jun 4.

PMID:
26040420
20.

Role of SRC-like adaptor protein (SLAP) in immune and malignant cell signaling.

Kazi JU, Kabir NN, Rönnstrand L.

Cell Mol Life Sci. 2015 Jul;72(13):2535-44. doi: 10.1007/s00018-015-1882-6. Epub 2015 Mar 13. Review.

PMID:
25772501
21.

The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Agarwal S, Kazi JU, Mohlin S, Påhlman S, Rönnstrand L.

Oncogene. 2015 Aug 27;34(35):4581-90. doi: 10.1038/onc.2014.383. Epub 2014 Dec 1.

PMID:
25435369
22.

SOCS6 is a selective suppressor of receptor tyrosine kinase signaling.

Kabir NN, Sun J, Rönnstrand L, Kazi JU.

Tumour Biol. 2014 Nov;35(11):10581-9. doi: 10.1007/s13277-014-2542-4. Epub 2014 Aug 30. Review.

PMID:
25172101
23.

Keratin 19 expression correlates with poor prognosis in breast cancer.

Kabir NN, Rönnstrand L, Kazi JU.

Mol Biol Rep. 2014 Dec;41(12):7729-35. doi: 10.1007/s11033-014-3684-6. Epub 2014 Aug 26.

PMID:
25156534
24.

SOCS proteins in regulation of receptor tyrosine kinase signaling.

Kazi JU, Kabir NN, Flores-Morales A, Rönnstrand L.

Cell Mol Life Sci. 2014 Sep;71(17):3297-310. doi: 10.1007/s00018-014-1619-y. Epub 2014 Apr 5. Review.

PMID:
24705897
25.

SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K.

Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022.

26.

EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.

Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, Neumann D, Rönnstrand L, Påhlman S.

Biochem Biophys Res Commun. 2014 Feb 28;445(1):163-9. doi: 10.1016/j.bbrc.2014.01.165. Epub 2014 Feb 3.

27.

Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling.

Kazi JU, Agarwal S, Sun J, Bracco E, Rönnstrand L.

J Cell Sci. 2014 Feb 1;127(Pt 3):653-62. doi: 10.1242/jcs.140590. Epub 2013 Nov 27. Erratum in: J Cell Sci. 2014 May 15;127(Pt 10):2376.

28.

The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.

Sun J, Mohlin S, Lundby A, Kazi JU, Hellman U, Påhlman S, Olsen JV, Rönnstrand L.

Oncogene. 2014 Nov 13;33(46):5360-9. doi: 10.1038/onc.2013.479. Epub 2013 Nov 11.

PMID:
24213578
29.

Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Kazi JU, Kabir NN, Rönnstrand L.

Med Oncol. 2013 Dec;30(4):757. doi: 10.1007/s12032-013-0757-7. Epub 2013 Oct 31. Review.

PMID:
24174318
30.

Differential activity of c-KIT splice forms is controlled by extracellular peptide insert length.

Phung B, Steingrímsson E, Rönnstrand L.

Cell Signal. 2013 Nov;25(11):2231-8. doi: 10.1016/j.cellsig.2013.07.011. Epub 2013 Jul 21.

PMID:
23880320
31.

The basic helix-loop-helix (bHLH) proteins in breast cancer progression.

Kabir NN, Rönnstrand L, Kazi JU.

Med Oncol. 2013;30(3):666. doi: 10.1007/s12032-013-0666-9. Epub 2013 Jul 23. No abstract available.

PMID:
23877873
32.

Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.

Agarwal S, Kazi JU, Rönnstrand L.

J Biol Chem. 2013 Aug 2;288(31):22460-8. doi: 10.1074/jbc.M113.474072. Epub 2013 Jun 26.

33.

Enhanced SOX10 and KIT expression in cutaneous melanoma.

Rönnstrand L, Phung B.

Med Oncol. 2013;30(3):648. doi: 10.1007/s12032-013-0648-y. Epub 2013 Jun 26. No abstract available.

PMID:
23801280
34.

The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.

Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L.

Cell Signal. 2013 Sep;25(9):1852-60. doi: 10.1016/j.cellsig.2013.05.016. Epub 2013 May 21.

PMID:
23707526
35.

Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling.

Kazi JU, Rönnstrand L.

Mol Oncol. 2013 Jun;7(3):693-703. doi: 10.1016/j.molonc.2013.02.020. Epub 2013 Mar 19.

36.

The presence or absence of IL-3 during long-term culture of Flt3-ITD and c-Kit-D816V expressing Ba/F3 cells influences signaling outcome.

Kazi JU, Sun J, Rönnstrand L.

Exp Hematol. 2013 Jul;41(7):585-7. doi: 10.1016/j.exphem.2013.03.005. Epub 2013 Mar 22. No abstract available.

PMID:
23528808
37.

Deregulation of protein phosphatase expression in acute myeloid leukemia.

Kabir NN, Rönnstrand L, Kazi JU.

Med Oncol. 2013 Jun;30(2):517. doi: 10.1007/s12032-013-0517-8. Epub 2013 Feb 26.

PMID:
23440723
38.

Protein kinase C expression is deregulated in chronic lymphocytic leukemia.

Kabir NN, Rönnstrand L, Kazi JU.

Leuk Lymphoma. 2013 Oct;54(10):2288-90. doi: 10.3109/10428194.2013.769220. Epub 2013 Feb 16. No abstract available.

PMID:
23343179
39.

FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL).

Kabir NN, Rönnstrand L, Kazi JU.

Med Oncol. 2013 Mar;30(1):462. doi: 10.1007/s12032-013-0462-6. Epub 2013 Jan 19. No abstract available.

PMID:
23335073
40.

Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling.

Kazi JU, Rönnstrand L.

PLoS One. 2012;7(12):e53509. doi: 10.1371/journal.pone.0053509. Epub 2012 Dec 31.

41.

FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.

Kazi JU, Rönnstrand L.

Mol Oncol. 2013 Jun;7(3):402-18. doi: 10.1016/j.molonc.2012.11.003. Epub 2012 Nov 29.

42.

Stem cell factor receptor/c-Kit: from basic science to clinical implications.

Lennartsson J, Rönnstrand L.

Physiol Rev. 2012 Oct;92(4):1619-49. doi: 10.1152/physrev.00046.2011. Review.

43.

Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3.

Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L.

J Biol Chem. 2012 Oct 19;287(43):36509-17. doi: 10.1074/jbc.M112.376111. Epub 2012 Sep 5.

44.

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.

Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S, Tabayashi T, Bergholz U, Kazi JU, Rönnstrand L, Stocking C, Koeffler HP.

Blood. 2012 Oct 18;120(16):3310-7. doi: 10.1182/blood-2011-10-388611. Epub 2012 Aug 31.

45.

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.

Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.

Blood. 2012 Apr 26;119(17):4026-33. doi: 10.1182/blood-2011-07-365726. Epub 2012 Mar 12.

46.

HIF-2α expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1α is repressed.

Munksgaard Persson M, Johansson ME, Monsef N, Planck M, Beckman S, Seckl MJ, Rönnstrand L, Påhlman S, Pettersson HM.

Am J Pathol. 2012 Feb;180(2):494-504. doi: 10.1016/j.ajpath.2011.10.014. Epub 2011 Nov 21.

PMID:
22115707
47.

C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation.

Phung B, Sun J, Schepsky A, Steingrimsson E, Rönnstrand L.

PLoS One. 2011;6(8):e24064. doi: 10.1371/journal.pone.0024064. Epub 2011 Aug 24.

48.

3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.

Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, Ballaschk A, Kramb JP, Plutizki S, Rönnstrand L, Dannhardt G, Fischer T.

Ann Hematol. 2012 Mar;91(3):331-44. doi: 10.1007/s00277-011-1311-3. Epub 2011 Sep 1.

PMID:
21881825
49.

Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.

Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.

Br J Haematol. 2011 Oct;155(2):198-208. doi: 10.1111/j.1365-2141.2011.08819.x. Epub 2011 Aug 16.

PMID:
21848891
50.

Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD.

Razumovskaya E, Sun J, Rönnstrand L.

Biochem Biophys Res Commun. 2011 Aug 26;412(2):307-12. doi: 10.1016/j.bbrc.2011.07.089. Epub 2011 Jul 28. Erratum in: Biochem Biophys Res Commun. 2011 Nov 11;415(1):214.

PMID:
21820407

Supplemental Content

Loading ...
Support Center